These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34690750)

  • 1. Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis.
    Zhong P; Zeng H; Huang M; He G; Chen Z
    Front Pharmacol; 2021; 12():695182. PubMed ID: 34690750
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.
    Alhindi Y; Avery A
    Contemp Clin Trials Commun; 2022 Aug; 28():100944. PubMed ID: 35812819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Shi FH; Li H; Cui M; Zhang ZL; Gu ZC; Liu XY
    Front Pharmacol; 2018; 9():576. PubMed ID: 29915538
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
    Wu W; Tong HM; Li YS; Cui J
    Endocrine; 2024 Mar; 83(3):571-584. PubMed ID: 38097902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
    Zhang R; Hou QC; Li BH; Deng L; Yang YM; Li TX; Yao XQ; Yang LL; Lin XL; Liao YQ; Wang L; Liu YP; Tan J; Wan ZW; Shuai P
    Front Endocrinol (Lausanne); 2023; 14():1132004. PubMed ID: 37455913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.
    Zhang L; Hua Z; Fang Z; Wei J; Lin Y
    J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38874130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.
    Hu S; Su X; Fan G
    Diabetol Metab Syndr; 2023 Oct; 15(1):218. PubMed ID: 37891683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
    Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
    Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
    Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
    Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
    Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
    Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
    Wilkinson L; Hunt B; Johansen P; Iyer NN; Dang-Tan T; Pollock RF
    Diabetes Ther; 2018 Jun; 9(3):951-961. PubMed ID: 29557057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.